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Though rare, rituximab has been reported to induce severe pulmonary edema. We describe the first report of ECLS utilization for
this indication. A 31-year-old female with severe thrombotic thrombocytopenic purpura developed florid pulmonary edema after
rituximab infusion. Despite advanced ventilatory settings, she developed severe respiratory acidosis and remained hypoxemic with
a significant vasopressor requirement. Since her pulmonary insult was likely transient, ECLS was considered. Due to combined
cardiorespiratory failure, she received support with peripheral venoarterial ECLS. During her ECLS course, she received daily
plasmapheresis and high dose steroids. Her pulmonary function recovered and she was decannulated after 8 days. She was
discharged after 23 days without residual sequelae.
1. Introduction
Rituximab, a monoclonal anti-CD20 antibody used in the
treatment of hematologic and autoimmune diseases, though
rare, has been reported to induce life-threatening pulmonary
edema attributed to a large cytokine release [1, 2]. The
management of severe noncardiogenic pulmonary edema
with extracorporeal life support (ECLS) has been described
[3]. Further, ECLS has been utilized for pulmonary edema
secondary to cytokine release in the setting of transfusion-
related acute lung injury [4] and tumor lysis syndrome [5].
We present here a case of acute florid pulmonary edema
due to a rituximab infusion, the first reported successfully
managed with ECLS. This case report was approved by
the Washington University in St. Louis School of Medicine
Internal Review Board with the patient’s consent.
2. Case Presentation
This 31-year-old female suffered from thrombotic thrombo-
cytopenic purpura (TTP) with multiple relapses requiring
plasmapheresis, steroids, and rituximab. Two weeks prior to
presentation, she was hospitalized for a TTP relapse with
a platelet count of 17,000, hemoglobin of 7.9 g/dl, lactate
dehydrogenase of 1,246 units/L, undetectable ADAMTS13
activity level, and ADAMTS13 inhibitor level greater than
8 inhibitor units. While admitted, she underwent seven
rounds of plasmapheresis andwas started onweekly low-dose
rituximab (100mg fixed dose) per clinical trial. She received
two doses during admission, which she tolerated with only
mild itching. At that time, she was receiving prednisone,
100mg daily and premedication with diphenhydramine and
acetaminophen. She presented 6 days after discharge for
week three of low-dose rituximab, receiving the same pre-
medications, during which she developed respiratory dis-
tress. The infusion was immediately stopped; however, she
quickly deteriorated requiring intubation, producing copious
white frothy sputum that required continuous suctioning.
A chest radiograph confirmed severe bilateral pulmonary
edema. Despite advanced ventilatory settings and inhaled
nitric oxide (NO), she developed respiratory shock (pH: 7.19,
pCO
2
: 63mmHg, pO
2
: 42mmHg). Her lactate peaked at
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18.0mmol/L and she became oliguric. A transthoracic echo
(TTE) demonstrated grossly normal left ventricular (LV) and
right ventricular (RV) function and ejection fraction (EF)
of 70%, with pulmonary artery systolic pressures (PASP)
of 36mmHg. She became difficult to oxygenate requiring
escalating ventilatory settings, pressure-control ventilation
with a peak inspiratory pressure of 40 cm H
2
O, and a plateau
pressure of 20 cm H
2
O giving a mean airway pressure of
26–30 cm H
2
O, with a fraction of inspired oxygen of 100%.
Her acidosis, elevated intrathoracic pressure, and increased
pulmonary vascular resistance led to a significant vasopressor
requirement. This was confirmed with a central venous
catheter which measured her central venous pressure at
28mmHg. Serial bedside ultrasounds were performed which
showed a deterioration in left ventricular function with poor
ventricular filling. An esophageal Doppler was placed which
showed a cardiac output of 2.1 L/m for a cardiac index of
1.0 L/min/m2 (body surface area: 2.2m2).
As this insult was anticipated to be transient and
reversible, venoarterial (VA) ECLS was initiated. After 3,000
units of intravenous heparin, percutaneous cannulation was
performed with a 25-French multistage cannula in the
femoral vein and a 17-French arterial cannula in the common
femoral artery. In addition, a 5-French vascular sheath
was inserted into the superficial femoral artery for distal
limb perfusion. All cannulas were placed with ultrasound
guidance. The ECLS circuit initially provided a flow of
2.3–2.7 L/min/m2 with a sweep gas flow rate of 8 L/min at
100% oxygen. Once the patient stabilized a repeat TTE was
performed which showed severe LV dysfunction with an EF
of 25% and PASP similar to the previous.
Vasopressors and NO were immediately weaned. With
oliguria and pulmonary edema, continuous venovenous
hemodialysis (CVVHD) was initiated. Despite a negative
fluid balance, chest radiographs worsened until ECLS Day 3.
By Day 5, the radiographs began to improve and she was able
to be weaned to conventional pressure-control settings with
40% FiO
2
. At this time, an echocardiogram demonstrated
normal cardiac function. She received daily plasmapheresis
and high dose steroids, methylprednisolone 1mg/kg. As her
acidosis corrected, the sweep speed was decreased. OnDay 6,
ECLS weaning was initiated gradually. She was decannulated
on Day 8. After decannulation her pulmonary status contin-
ued to improve and she was extubated the next day.
Her course was well tolerated, without major complica-
tions. After decannulation she did well and was discharged
after a total hospital stay of 23 days. She did develop acute
kidney injury (AKI) prior to ECLS cannulation, further
exacerbating her pulmonary edema. She received CVVHD
with aggressive volume removal, net 300ml/hour with
plasmapheresis. Her renal function gradually improved and
returned to baseline prior to discharge. Additionally, diffuse
oral mucosal bleeding began immediately after cannulation.
Though no intervention was necessary, due to this and
her low platelet count, she was not anticoagulated. While
maintained on ECLS, the initial goal platelet count was
greater than 20,000/mm3. However, once she developed oral
mucosal bleeding, the goal was modified to greater than
40,000/mm3. She received 9 platelet transfusions during her
ECLS course.
When cannulated for ECLS her ADAMTS13 activity level
was undetectable and her ADAMTS13 inhibitor level was
4.4 inhibitor units. Her platelet count reached a nadir of
12,000/mm3. By ECLS Day 7 she improved to an ADAMTS13
activity level of 61% and an inhibitor level of 0.4 inhibitor
units. In total, she received 13 rounds of plasmapheresis and
was transitioned to 100mg prednisone daily. Since she is no
longer a candidate for rituximab and has a high probability of
relapse, she has been referred for splenectomy.
3. Discussion
Rituximab decreases the production of antibodies to
ADAMTS13, leading to increased ADAMTS13 activity and
cleavage of the large von Willebrand Factor multimers, thus,
preventing the multimer-induced platelet aggregation and
microthrombi formation occurring with TTP [6]. Expansion
of rituximab use has resulted in the reporting of rare adverse
events in postmarketing surveillance [7]. Cytokine release
syndrome (CRS) has been reported, though this typically
occurs after the first infusion [2].
Initially, our patient had a broad differential diagnosis.
Her rapid deterioration, frothy sputum, chest radiograph,
and timing made pulmonary edema due to the rituximab
infusion the most likely diagnosis. Rituximab induced pul-
monary edema due to the fact that CRS has been previously
reported and shown to be reversible [1]. Therefore, despite
her grave condition, we anticipated that she had a potentially
recoverable insult.
By the time ECLS was considered she required high
levels of support, both respiratory and hemodynamic. At
this time, the patient was on advanced ventilator settings
with high peak inspiratory andmean airway pressures, which
causes a decrease in left ventricular stroke volume and cardiac
output [8]. Additionally, acidosis, metabolic or respiratory
(our patient suffered from both), is known to lead to a
decreased stroke volume due to the negative inotropic effects
of the acidosis [9]. This likely resulted in her hemodynamic
collapse, and, therefore, VA, rather than venovenous (VV)
ECLS, was initiated. In this instance, the VA ECMO strategy
allowed for decreased vasopressor requirements and helped
to improve renal blood flow. However, if considered earlier,
VV ECLS may have prevented her hemodynamic compro-
mise by eliminating the respiratory acidosis, the elevated
intrathoracic pressure and the increased pulmonary vascular
resistance, and, therefore, the need for VA support.
As our patient’s cardiac function improved such that she
essentially had only respiratory failure, there was concern for
differential hypoxia. As cardiac function recovered, due to
her cannulation strategy, her cardiac output would consist
of poorly oxygenated blood preferentially perfusing the
coronaries and cerebral vessels. Further, a “dual circuit” can
develop, such that deoxygenated blood recirculates from
upper body (heart, brain, and upper extremities) through
the superior vena cava (SVC), heart, lungs, and great vessels.
A second circuit is established consisting of the descend-
ing aorta, lower body, inferior vena cava (IVC), and the
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ECLS circuit [10]. To monitor for this, our patient had
bilateral radial arterial access with arterial blood gas analysis
from each. Had they demonstrated a developing differential
hypoxia, alternative cannulation strategies would have been
necessary, possibly including advancing the IVC catheter into
the SVCor placing additional venous or arterial cannulas [11].
Placement of a subclavian arterial cannula in addition to, or
rather than, a femoral cannula also would have abolished this
phenomenon.
While the literature remains inconclusive, some suggest
significant differences in survival based on cannulation strat-
egy. Interestingly, veno-venoarterial (VVA) ECLS is touted
by some as having superior survival, to both VV and VA, in
patients with a primary pulmonary pathology [12]. This can-
nulation strategy utilizes a second outflow cannula, returning
oxygenated blood to both the arterial and the venous system.
If venous return is insufficient to support the increase in
outflow, a second venous return cannula can be used. Indeed,
despite the lack of differential hypoxia, our patient may have
benefited from VVA ECLS by improving the oxygenation
which would allow for lung protective ventilator settings ear-
lier. Additionally, the preoxygenated blood flowing through
the pulmonary system would lead to decreased pulmonary
vascular resistance and further increase preload.
Since her hemodynamics continuously improved after
VA ECLS initiation, though considered, the decision was
made to not pursue a cannula reconfiguration. In addition
to cannula reconfiguration, alternative therapies directed at
the treatment of CRS could have been considered, rather than
plasmapheresis. Recent literature has shown some promise
with the anti-IL-6RmAb tocilizumab [13].Though reports of
its utilization are sparse, with only one report describing its
utilization in 9 pediatric patients, the results are encouraging
[14].
As new therapies are developed for hematologic, onco-
logic, and autoimmune diseases, the possibility of severe
pulmonary edema related toCRSmay becomemore frequent.
Here, we demonstrate the utility of ECLS as a temporizing
mechanism, though note that further research is necessary to
determine optimal cannulation strategies.
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